Publications

Detailed Information

GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2AAdenosine Receptor

Cited 0 time in Web of Science Cited 11 time in Scopus
Authors

Shiriaeva, Anna; Park, Daejin; Kim, Gyudong; Lee, Yoonji; Hou, Xiyan; Jarhad, Dnyandev B.; Kim, Gibae; Yu, Jinha; Hyun, Young Eum; Kim, Woomi; Gao, Zhan-Guo; Jacobson, Kenneth A.; Han, Gye Won; Stevens, Raymond C.; Jeong, Lak Shin; Choi, Sun; Cherezov, Vadim

Issue Date
2022-09
Publisher
American Chemical Society
Citation
Journal of Medicinal Chemistry, Vol.65 No.17, pp.11648-11657
Abstract
© 2022 American Chemical Society. All rights reserved.Modulators of the G protein-coupled A2Aadenosine receptor (A2AAR) have been considered promising agents to treat Parkinson's disease, inflammation, cancer, and central nervous system disorders. Herein, we demonstrate that a thiophene modification at the C8 position in the common adenine scaffold converted an A2AAR agonist into an antagonist. We synthesized and characterized a novel A2AAR antagonist, 2 (LJ-4517), with Ki= 18.3 nM. X-ray crystallographic structures of 2 in complex with two thermostabilized A2AAR constructs were solved at 2.05 and 2.80 Å resolutions. In contrast to A2AAR agonists, which simultaneously interact with both Ser2777.42and His2787.43, 2 only transiently contacts His2787.43, which can be direct or water-mediated. The n-hexynyl group of 2 extends into an A2AAR exosite. Structural analysis revealed that the introduced thiophene modification restricted receptor conformational rearrangements required for subsequent activation. This approach can expand the repertoire of adenosine receptor antagonists that can be designed based on available agonist scaffolds.
ISSN
0022-2623
URI
https://hdl.handle.net/10371/185583
DOI
https://doi.org/10.1021/acs.jmedchem.2c00462
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share